| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Mogroside III-E targets inflammatory pathways and Toll-like receptors (TLR). It can inhibit the release of nitric oxide (NO) and has anti-pulmonary fibrosis effects. It also exhibits anti-inflammatory activity. Its effects on glucose metabolism and oxidative damage are consistent with the broader class of mogrosides.
|
|---|---|
| ln Vitro |
In vitro, Mogroside III-E demonstrates significant anti-inflammatory activity. It inhibits the release of NO from activated macrophages. This activity is a key indicator of its potential to reduce inflammation. It also shows anti-pulmonary fibrosis effects, suggesting it can modulate fibrotic pathways. Its antioxidant properties protect against oxidative damage.
|
| ln Vivo |
In vivo, Mogroside III-E has been studied for its anti-pulmonary fibrosis effects. Its anti-inflammatory activity suggests it could be beneficial in models of chronic inflammation. Research suggests it may help regulate glucose metabolism and support metabolic and cardiovascular health. Further studies are needed to fully characterize its in vivo pharmacology.
|
| Enzyme Assay |
The in vitro NO inhibition assay is a primary method for evaluating Mogroside III-E's anti-inflammatory activity. Macrophage cell lines, such as RAW 264.7, are stimulated with LPS to induce NO production. The compound is added, and the amount of nitrite (a stable metabolite of NO) in the culture medium is measured using the Griess reagent. The IC50 for NO inhibition is calculated.
|
| Cell Assay |
In vitro cell culture studies for Mogroside III-E utilize macrophage cell lines to study its anti-inflammatory effects. The expression of inflammatory cytokines (TNF-α, IL-6) and iNOS is measured by ELISA or qPCR. For anti-fibrotic studies, lung fibroblasts can be treated with TGF-β to induce fibrosis, and the compound's ability to reduce collagen deposition can be assessed.
|
| Animal Protocol |
In vivo animal experiments for Mogroside III-E have been performed in models of pulmonary fibrosis. In these studies, the compound is administered to mice, and fibrosis is induced by agents like bleomycin. Lung tissue is analyzed for histopathology (collagen deposition) and molecular markers of fibrosis (e.g., α-SMA, fibronectin). Its anti-inflammatory effects can be studied in models of acute inflammation.
|
| ADME/Pharmacokinetics |
Mogroside III-E has a molecular formula of C48H82O19 and a molecular weight of 963.15 g/mol. It is a solid compound that is soluble in water and organic solvents like DMSO. As a glycoside, it is more polar than its aglycone. It is typically stored as a powder at -20°C for long-term stability. Its stability is maintained under recommended storage conditions.
|
| Toxicity/Toxicokinetics |
Toxicological data for Mogroside III-E are limited, as it is a research compound. As a natural component of monk fruit, it is generally considered safe. However, as a research compound, it is not intended for therapeutic use, and comprehensive toxicity studies are not available. Standard safety precautions should be followed.
|
| References | |
| Additional Infomation |
It has been reported that mogroside III-E exists in monk fruit (Siraitia grosvenorii), and relevant data are available.
See also: Mogroside III (note moved to). Mogroside III-E is a research compound with no clinical approval. It is a valuable tool for studying the anti-inflammatory and anti-fibrotic effects of cucurbitane-type compounds. Its ability to inhibit NO release and its anti-pulmonary fibrosis effects make it a compound of interest for research into inflammatory and fibrotic diseases. |
| Molecular Formula |
C48H82O19
|
|---|---|
| Molecular Weight |
963.1533
|
| Exact Mass |
962.545
|
| CAS # |
88901-37-5
|
| PubChem CID |
102350789
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
1050.4±65.0 °C at 760 mmHg
|
| Flash Point |
589.1±34.3 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.619
|
| LogP |
1.7
|
| Hydrogen Bond Donor Count |
13
|
| Hydrogen Bond Acceptor Count |
19
|
| Rotatable Bond Count |
14
|
| Heavy Atom Count |
67
|
| Complexity |
1720
|
| Defined Atom Stereocenter Count |
25
|
| SMILES |
C[C@H](CC[C@H](C(C)(C)O)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)[C@H]3CC[C@@]4([C@@]3(C[C@H]([C@@]5([C@H]4CC=C6[C@H]5CC[C@@H](C6(C)C)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O)C)O)C)C
|
| InChi Key |
QATISCJMIITVAB-CNEPTXDISA-N
|
| InChi Code |
InChI=1S/C48H82O19/c1-21(9-13-31(45(4,5)61)66-43-40(37(58)34(55)27(20-51)64-43)67-42-39(60)36(57)33(54)26(19-50)63-42)22-15-16-46(6)28-12-10-23-24(48(28,8)29(52)17-47(22,46)7)11-14-30(44(23,2)3)65-41-38(59)35(56)32(53)25(18-49)62-41/h10,21-22,24-43,49-61H,9,11-20H2,1-8H3/t21-,22-,24-,25-,26-,27-,28+,29-,30+,31-,32-,33-,34-,35+,36+,37+,38-,39-,40-,41+,42+,43+,46+,47-,48+/m1/s1
|
| Chemical Name |
(2R,3R,4S,5S,6R)-2-[[(3S,8S,9R,10R,11R,13R,14S,17R)-17-[(2R,5R)-5-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-hydroxy-6-methylheptan-2-yl]-11-hydroxy-4,4,9,13,14-pentamethyl-2,3,7,8,10,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~103.83 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (2.60 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (2.60 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (2.60 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0383 mL | 5.1913 mL | 10.3826 mL | |
| 5 mM | 0.2077 mL | 1.0383 mL | 2.0765 mL | |
| 10 mM | 0.1038 mL | 0.5191 mL | 1.0383 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
